Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC - Trial NCT06069570
Access comprehensive clinical trial information for NCT06069570 through Pure Global AI's free database. This Phase 1 trial is sponsored by Kiromic BioPharma Inc. and is currently Not yet recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Kiromic BioPharma Inc.
Timeline & Enrollment
Phase 1
Dec 01, 2023
Jan 01, 2027
Primary Outcome
Number of participants with Adverse Events (AE) and/or Dose Limiting Toxicities (DLT) as a Measurement of Safety and Tolerability of KB-GDT-01 in Combination with LDRT
Summary
This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells
 after receiving low dose radiotherapy in participants with metastatic non-small cell lung
 cancer to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06069570
Non-Device Trial